<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02167906</url>
  </required_header>
  <id_info>
    <org_study_id>9356</org_study_id>
    <nct_id>NCT02167906</nct_id>
  </id_info>
  <brief_title>Impact of Hand Osteoarthritis on Arterial Stiffness</brief_title>
  <official_title>Impact of Hand Osteoarthritis on Arterial Stiffness</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Montpellier</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Montpellier</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients affected by osteoarthritis (OA) have an increase overall mortality compared to the&#xD;
      general population, mainly due to cardiovascular diseases. OA patients without cardiovascular&#xD;
      risk have a 10 years cardiovascular events higher of around 15-30 %. Although the molecular&#xD;
      mechanisms are still not well known, the structure and function of the vessel wall can be&#xD;
      affected by several inflammatory and metabolic parameters during OA.These functional and&#xD;
      structural changes of the arterial wall leads to arterial stiffness, measured by the&#xD;
      pulse-wave velocity (PWV). PWV is the most widely used technique to assess arterial stiffness&#xD;
      and has been shown to have predictive value for morbidity and mortality. In our study, we&#xD;
      planned to compare arterial stiffness in OA patients with healthy subjects.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>September 2014</start_date>
  <completion_date type="Anticipated">September 2016</completion_date>
  <primary_completion_date type="Anticipated">September 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>carotid-femoral arterial stiffness</measure>
    <time_frame>within the first 15 days after inclusion</time_frame>
    <description>To assess the carotid-femoral arterial stiffness determined by measuring the PWV in patients with hand OA compared to healthy subjects.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>hand oa patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>assess the carotid-femoral arterial stiffness determined by measuring the PWV</description>
  </arm_group>
  <arm_group>
    <arm_group_label>without Hand OA patients</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>assess the carotid-femoral arterial stiffness determined by measuring the PWV</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>arterial stiffness measurement</intervention_name>
    <arm_group_label>hand oa patients</arm_group_label>
    <arm_group_label>without Hand OA patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with clinical hand OA defined according to the ACR (American College of&#xD;
             Rheumatology) criteria.&#xD;
&#xD;
          -  Patients with radiographic hand OA defined according to the Kellgren&#xD;
&#xD;
          -  Lawrence criteria (≥ 2).&#xD;
&#xD;
          -  Steady dose of statins for at least one month.&#xD;
&#xD;
          -  Subject affiliated to a social security scheme&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Rheumatoid arthritis, psoriatic arthritis or other inflammatory arthritis diseases.&#xD;
&#xD;
          -  History of arterial hypertension treated and / or uncontrolled (SBP &gt; 140 mmHg and DBP&#xD;
             (diastolic blood pressure) &gt; 90 mmHg)&#xD;
&#xD;
          -  Diabetes (fasting blood glucose &gt; 7 mmol/L)&#xD;
&#xD;
          -  Obesity (BMI &gt; 35 kg/m²)&#xD;
&#xD;
          -  Chronic renal failure defined by a glomerular filtration rate &lt;60 ml/min/1,73m ².&#xD;
&#xD;
          -  Patient with uncontrolled cardiovascular disease or a personal history of&#xD;
             cardiovascular events (myocardial infarction and angina, occlusive arterial disease,&#xD;
             stroke)&#xD;
&#xD;
          -  Pregnant or breastfeeding, or premenopausal and not taking an effective contraception&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Yves Marie PERS, MD</last_name>
    <phone>04 67 33 72 31</phone>
    <email>ym-pers@chu-montpellier.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>UH Montpellier</name>
      <address>
        <city>Montpellier</city>
        <zip>34 295</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Yves-Marie PERS, MD</last_name>
      <phone>04 67 33 72 31</phone>
      <email>ym-pers@chu-montpellier.fr</email>
    </contact>
    <investigator>
      <last_name>Yves Marie PERS, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2014</verification_date>
  <study_first_submitted>June 17, 2014</study_first_submitted>
  <study_first_submitted_qc>June 17, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 19, 2014</study_first_posted>
  <last_update_submitted>June 17, 2014</last_update_submitted>
  <last_update_submitted_qc>June 17, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 19, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

